UFP Technologies (UFPT) Margin Dip To 11.3% Tests Bullish MedTech Growth Narrative
UFP Technologies, Inc. UFPT | 0.00 |
UFP Technologies (UFPT) has put fresh numbers on the board for Q1 2026, with recent quarterly revenue sitting around US$148.9 million in Q4 2025, basic EPS of US$2.28 and trailing twelve month EPS of US$8.87 helping frame the latest report. Over the last year, the company has seen total revenue move from US$504.4 million on a trailing basis in Q4 2024 to US$602.8 million in Q4 2025. Over the same period, trailing net income excluding extra items shifted from US$59.0 million to US$68.3 million and EPS went from US$7.69 to US$8.87, alongside earnings growth of 15.8% and a small margin step down from 11.7% to 11.3%. This keeps the focus firmly on profitability quality and where margins go next.
See our full analysis for UFP Technologies.With the numbers on the table, the next step is to set these results against the main narratives around UFP Technologies to see which stories hold up and which start to look stretched.
Margins Hold at Around 11% Despite Cost Pressures
- Trailing net profit margin sits at 11.3%, a small step down from 11.7% a year earlier, while trailing net income excluding extra items moved from US$59.0 million to US$68.3 million over the same period.
- Bears highlight customer concentration and labor issues as threats to profitability, and the slight margin dip gives that view something to point to, yet:
- Annual earnings still grew 15.8% on a trailing basis, which runs against the idea that cost and workforce issues are already heavily eroding profits.
- Multi year earnings growth of 29.8% per year suggests the business has previously absorbed pressures like rising input costs and acquisitions while keeping margins in a relatively tight range.
15.8% Earnings Growth Meets Slower Pace Than 5 Year Trend
- On a trailing basis, earnings grew 15.8% over the last year compared with a 29.8% per year average over five years, while trailing twelve month revenue moved from US$504.4 million in Q4 2024 to US$602.8 million in Q4 2025.
- Bullish investors argue UFP can sustain above market growth thanks to MedTech exposure, recurring programs, and efficiency gains, and the data both supports and stretches that view:
- The 15.8% earnings growth and higher trailing EPS of US$8.87 versus US$7.69 a year earlier are consistent with a business that has continued to grow, rather than stalling.
- The gap between the latest 15.8% growth and the 29.8% five year average shows the recent pace is more moderate than the longer trend, which bulls need to reconcile with expectations for strong future expansion.
Valuation Sits Between Peer Multiples And DCF Fair Value
- At a share price of US$212.43, UFP Technologies trades on a trailing P/E of 24x, close to peers at 24.1x and a little above the US Medical Equipment industry at 23.6x, while a DCF fair value of US$354.88 sits well above both the market price and the consensus analyst target of US$324.50.
- Consensus narrative suggests the company’s investments and margin outlook can justify that gap, yet the numbers give a mixed message:
- Peer like P/E and 15.8% trailing earnings growth do not obviously flag an outlier premium, which fits with a market that is pricing UFP similarly to comparable stocks despite its multi year growth record.
- The DCF fair value being materially above the current price, and above the consensus target, assumes the recent moderation from 29.8% five year earnings growth to 15.8% is not a lasting shift, which is something each investor needs to test against their own expectations.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for UFP Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If the mix of bull and bear arguments here feels finely balanced, take a closer look at the underlying data and decide quickly where you stand. Then round out your view by checking the 2 key rewards.
See What Else Is Out There
UFP Technologies is facing a slower 15.8% earnings pace than its 29.8% multi year trend and modest margin compression, which leaves valuation expectations more finely balanced.
If that mix of moderating growth and a full looking 24x P/E makes you cautious, compare it with companies screened for 51 high quality undervalued stocks to see where the market may be pricing in more upside today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
